Drug Trial Radar · NCT06673498
Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery
Last checked: Nov 20, 2026Latest source record: Nov 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Nov 10, 2024
Primary completion
Nov 30, 2025
Study completion Nov 30, 2025
Sponsor
- Lead sponsor
- Anhui Provincial HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Nov 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the efficacy and safety of lusutrombopag combined with recombinant human thrombopoietin for the treatment of thrombocytopenia in patients with chronic liver disease destined to undergo elective invasive surgery.
Conditions
- Thrombocytopenia
Interventions
Lusutrombopag combined with recombinant human thrombopoietinDrug
After eligibility is confirmed, patients will begin treatment with Lusutrombopag +recombinant human thrombopoietin on Day 1, and study treatment will continue for 7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of respondents at day 8Time frame: Day 8
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
No.2 People's Hospital of Fuyang city
Fuyang, Anhui, China · Recruiting
Anhui province hospital
Hefei, Anhui, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.